Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
A look at the life and times of maverick businessman Chinnakannan Sivasankaran
The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
The Ministry of Science and Technology has approached about a dozen well-known scientists from across the world in an effort to bring them back to various departments under the ministry, said Jitendra Singh, minister of state (independent charge) for science and technology.
PepsiCo India's new CEO admits to being an ardent follower of the world's management gurus and they clearly mould his outlook.
Finalises blueprint to become pan-Indian dairy player; to set up plants in 6 states.
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
The future certainly looks good for Bangalore.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
BofA-ML mandated to find buyer for 27.5% stake in media group's holding firm
Essar Global Fund, the Ruia company that invested $1.3 billion in telecommunications, towers and business process outsourcing over the years, made $6.5 billion, a five-fold return, when it flipped these businesses, according to discussions the group has had with merchant bankers.
Phee Teik Yeoh, the recently anointed chief executive officer of the airline, speaks to Business Standard on his aim of changing the rule of the game in the aviation sector by redefining service and operational experience for travellers accustomed to mere functionality.
Looking to monetise assets not in Reliance Capital's core area of business.
Two months after launch, low-cost warrior AirAsia is expanding to uncharted routes in India.
Only one in five handsets sold in India this year is likely to be made locally.
Rakesh Gangwal's holding is considered FDI even though the majority stake in Caelum is held by NRIs
Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.
Sun-Ranbaxy are keen to complete the merger process.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances